GSK will launch 5 new drugs novo to expand simalutide Pfizer's most desired improvement is

Compiling coco J Just after the opening of the M Morgan Healthcare Conference, the CEO of GSK held a conference, and alexion announced the latest plans of ultomiris in another hall Takeda, Novo Nordisk, Pfizer and other major pharmaceutical companies released what research and development progress and company trends on the second day of the conference? Takeda completed the acquisition of shire only one year ago Christophe Weber, Takeda's chief executive, said when announcing the merger, the company has made great progress The two companies are operating as one company and have completed the integration of talents This is a remarkable achievement in terms of time and speed Takeda also plans to achieve another achievement in 2020, which is to achieve the goal of "carbon neutrality" this year Carbon neutralization refers to the measurement of the total amount of greenhouse gas emissions directly or indirectly generated by enterprises in a certain period of time By means of energy conservation and emission reduction, the carbon dioxide emissions generated by enterprises can be offset to achieve zero carbon dioxide emissions As a new form of environmental protection, it has been widely used Through the verified carbon compensation, Takeda will offset 4.5 million tons of carbon Weber points out that this is a financial commitment, we have tried to reduce carbon emissions, so Takeda can do it without changing its financial objectives In 2019, blue bird CEO Nick leschley told the JPM conference that four candidate drugs owned by the company are trying to solve difficult diseases (such as sickle cells, cancer, etc.) Now, Bluebird has launched gene therapy zynteglo to treat transfusion dependent beta thalassemia, the company's first product in Europe Two other FDA approved drugs are planned to be launched in Europe this year For leschley, the submission itself is an important milestone But most importantly, Bluebird has three products that have been approved by the U.S drug regulatory agency and are fully validated by the company What does Wall Street seem to be missing in its assessment of Pfizer? Chief executive Albert bourla said that's because they haven't seen revenue forecasts for the company's upcoming vaccines, including candidate drugs for the prevention of Clostridium difficile, meningococcal disease and respiratory syncytial virus in pregnant women In addition, Pfizer's gene therapy program, and most of its immunoinflammatory drugs Therefore, bourla believes that there is a huge difference between "Pfizer seen by analysts" and "Pfizer seen by Pfizer" But Pfizer also has some responsibility Bourla pointed out that for many years, we only focused on R & D, but did not hold a R & D day to share meaningful progress with the media, investors and analysts, which will change in March this year Dave ricks, chief executive of Eli Lilly, a leading diabetes company, predicts that price pressures will generally remain the same as the variety of drugs increases among diabetics In addition, he pointed out that although Lilly trulicity (dulaglutide) and Novo Nordisk's new oral rybelsus (simalutide) were in the early stage of the fight against GLP-1 receptor agonist drugs, he was full of confidence in the company's weekly injection hypoglycemic drugs According to ricks, Novo Nordisk gained market share to some extent at the expense of trulicity, but mainly at the expense of replacing other GLP-1 products, including its own product Victoza (lilalutide) Madskrogsgaard Thomsen, chief scientific officer of Novo Nordisk, and Marcus Schindler, senior vice president of global drug research and development, stressed that smalutide for injection or oral use showed promise beyond treatment for diabetes only The company is conducting prognosis trials for cardiovascular disease, diabetic retinopathy and chronic kidney disease At the same time, Novo Nordisk is further testing drugs for obese patients with nonalcoholic steatohepatitis without diabetes In addition, researchers outside the company have begun testing the drug for Alzheimer's and Parkinson's disease After buying the psoriasis drug otezla from Xinji in August last year at a high price of $13.4 billion, Amgen is now seeking to add new indications to the blockbuster by 2020 and expand it to the international market, said Bob Bradway, Amgen's chief executive The drug will help Amgen enrich its immunological products in the next few years, provided that Amgen can continue to implement the plan But Bradway said: "in the field of biopharmaceuticals, the focus is innovation, innovation, and reinvention, and Amgen's principle is implementation, implementation, and re implementation." So it doesn't sound like a problem GSK announced its $5.1 billion acquisition of tesaro ahead of the JPM Healthcare Conference in 2019, and re entered the field of cancer treatment Emma Walmsley, chief executive of GSK, pointed out that the deal brought not only the PARP inhibitor zejula, but also highly skilled employees with deep expertise in oncology, including research and development, regulation, medical affairs and market access, as well as sales representatives Professionals and sales knowledge will prepare GSK's three oncology products for market in 2020 In 2019, GSK's existing products continue to add new indications, such as zejula for first-line ovarian cancer maintenance treatment; trelegy for asthma treatment, challenging the lynparza of AstraZeneca and mosadon Walmsley said GSK is very focused on building channels for the next wave of growth, and the company expects to launch five new products in 2020 Five products are related to cancer, HIV and kidney diseases, including the long-term cabotegravir and rilpivirine product portfolio Although the U.S FDA's reply to the full response letter in December 2019 delayed the launch of the product portfolio, GSK is expected to successfully promote this year Alexion strives to support the sales growth of the old drug soliris through the new generation long-term product ultomiris for rare blood diseases In the process, the company has witnessed the performance of patients' expectations for new drugs exceeding expectations Alexion is not satisfied with only transferring the patient market to ultomiris, but also hopes to expand the market and plan to use the drug in the treatment of ALS Ludwig hantson, alexion's chief executive, said it was a high-risk, high return program But it looks like the company still wants to try.